Implications of de novo mutations in guiding drug discovery: A study of four neuropsychiatric disorders
Publication in refereed journal

香港中文大學研究人員
替代計量分析
.

其它資訊
摘要Recent studies have suggested an important role of de novo mutations (DNMs) in neuropsychiatric disorders. As DNMs are not subject to elimination due to evolutionary pressure, they are likely to have greater disruptions on biological functions. While a number of sequencing studies have been performed on neuropsychiatric disorders, the implications of DNMs for drug discovery remain to be explored.

In this study, we employed a gene-set analysis approach to address this issue. Four neuropsychiatric disorders were studied, including schizophrenia (SCZ), autistic spectrum disorders (ASD), intellectual disability (ID) and epilepsy. We first identified gene-sets associated with different drugs, and analyzed whether the gene-set pertaining to each drug overlaps with DNMs more than expected by chance. We also assessed which medication classes are enriched among the prioritized drugs. We discovered that neuropsychiatric drug classes were indeed significantly enriched for DNMs of all four disorders; in particular, antipsychotics and antiepileptics were the most strongly enriched drug classes for SCZ and epilepsy respectively. Interestingly, we revealed enrichment of several unexpected drug classes, such as lipid-lowering agents for SCZ and anti-neoplastic agents. By inspecting individual hits, we also uncovered other interesting drug candidates or mechanisms (e.g. histone deacetylase inhibition and retinoid signaling) that might warrant further investigations. Taken together, this study provided evidence for the usefulness of DNMs in guiding drug discovery or repositioning.
著者Hon-Cheong SO, Yui-Hang WONG
期刊名稱Journal of Psychiatric Research
出版年份2019
月份3
卷號110
出版社PERGAMON-ELSEVIER SCIENCE LTD
頁次83 - 92
國際標準期刊號0022-3956
語言英式英語
Web of Science 學科類別Psychiatry;Psychiatry

上次更新時間 2021-13-10 於 23:42